Open AccessLow Molecular Weight Fraction of Commercial Human Serum Albumin Induces Morphologic and Transcriptional Changes of Bone Marrow‐Derived Mesenchymal Stem Cells
Author(s) -
Bar-Or David,
Thomas Gregory W.,
Rael Leonard T.,
Gersch Elizabeth D.,
Rubinstein Pablo,
Brody Edward
Publication year - 2015
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2014-0293
Subject(s) - mesenchymal stem cell , chondrogenesis , stem cell , homing (biology) , microbiology and biotechnology , cxcr4 , bone marrow , chemistry , runx2 , cancer research , biology , immunology , inflammation , osteoblast , chemokine , biochemistry , in vitro , ecology
This study describes the effect of a biologic currently under development for the treatment of osteoarthritis to induce both cytoskeletal and transcriptional changes in bone marrow‐derived mesenchymal stem cells. These changes may have implications for the regenerative potential of low molecular weight fraction of commercial 5% human serum albumin and could help explain some of the clinical findings in the clinical trials conducted using this drug.